Wa’el Hashad joined Avanir Pharmaceuticals as President and Chief Executive Officer in July 2017.
Wa’el is a passionate leader with more than 25 years of experience in biopharmaceutical management, sales and marketing, within both the U.S. and international markets. Prior to joining Avanir he served as Executive Vice President and Chief Commercial Officer of Seres Therapeutics, where he spearheaded the strategy and development of several microbiome-based therapies.
Prior to Seres Therapeutics, Wa’el held several roles at Amgen, including Head of Global Marketing and Therapeutic Area Head for General Medicine; Regional Vice President for Japan, China and Asia-Pacific; and Regional Vice President for Africa and the Middle East regions. Earlier in his career, Wa’el served as Vice President of Cardiovascular and Diabetes Business at Boehringer Ingelheim. He also spent 18 years at Eli Lilly and Company, where he was responsible for the successful launch of several products.
Wa’el earned a Bachelor of Science in Pharmacy and Pharmaceutical Sciences from the College of Pharmacy, Cairo University, and a Master of Business Administration from the University of Akron in Ohio.